Nykode Therapeutics Denmark A/S: Financial statements 2023
CVR: 42038660
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Nykode Therapeutics Denmark A/S (CVR 42038660) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 52,927,648 and a net result of DKK 2,484,505 compared with DKK 1,895,426 the year before. That is an increase of 37% compared with the year before. Equity in the 2023 report amounted to DKK 5,358,013. The solvency ratio was 26.1%. The company had 31 employees in the financial year.
- Gross Profit
- DKK 52,927,648
- Profit/Loss
- DKK 2,484,505
- Equity
- DKK 5,358,013
- Total Assets
- DKK 20,504,300
- Employees
- 31
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 52.9M | 2.5M | 5.4M | 31 |
| 2022 | - | 38.6M | 1.9M | 2.9M | 23 |
| 2021 | - | 10.6M | 578K | 978K | 7 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Nykode Therapeutics Denmark A/S has published its annual report for 2022. Gross profit came to DKK 38,639,042, and the net result was DKK 1,895,426.
About Nykode Therapeutics Denmark A/S
Nykode Therapeutics Denmark A/S is a Danish company of the type Aktieselskab based in Kongens Lyngby, founded in 2021. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The company was previously named Vaccibody Denmark A/S. The management consists of Michael Thyrring Engsig. The board consists of Louise Stubbe (chair), Harald Gurvin and Michael Thyrring Engsig. The company is owned by Nykode Therapeutics ASA. The company has 11 employees (2026). In 2025, the company reported a gross profit of DKK 31,839,001 and a net result of DKK 1,347,127 compared with DKK 156,959 the year before. Equity in the 2025 report amounted to DKK 6,862,099.
